Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.96 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.96 |
| ▸ | HPGD | P15428 | 7/20 | 0.96 |
| ▸ | ESR1 | P03372 | 1/20 | 0.96 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.96 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.96 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | GGT1 | P19440 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin SCHEMBL11759331 | 0.98 | KDM4E (0.92) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL3689374 | 0.98 | KDM4E (0.92) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL10481798 | 0.98 | KDM4E (0.92) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL11811354 | 0.98 | KDM4E (0.92) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL11406181 | 0.98 | KDM4E (0.92) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL1353 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL10456693 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL7580 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL29350479 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL1331740 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122039173-A | Acidic copper plating brightening agent, acidic copper plating electroplating solution and electroplating process thereof | 惠州金晟新电子科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-118702708-A | Magnesium complex with aspirin or its hypoxia promoting type derivative as ligand, and preparation method and application thereof | 东南大学 | 2024-09-27 | — | — | CN | claimed |
| US-20220211621-A1 | LIPOSOMAL SUSTAINED-RELEASE COMPOSITIONS CONTAINING A THERAPEUTIC DRUG AND USE THEREOF | TLC BIOPHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | claimed |
| EP-4000602-A1 | NOVEL ZN(II)-NSAID-COMPLEX COMPOSITION | concrete flowers GmbH (AT) | 2022-05-25 | — | — | EP | claimed |
| WO-2020220000-A1 | LIPOSOMAL SUSTAINED-RELEASE COMPOSITIONS CONTAINING A THERAPEUTIC DRUG AND USE THEREOF | TLC BIOPHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | WO | claimed |
| CN-109821023-A | A kind of pH sensitive intelligent drug controlled release carrier and preparation method thereof | 江西光至金辉医疗制品有限公司 | 2019-05-31 | — | — | CN | claimed |
| CN-106674036-B | The method that non-organic solvent method synthesizes di-lysine-aspirin | 河南中医学院 | 2018-08-14 | — | — | CN | claimed |
| CN-106674036-A | Method for synthesizing aspirin-dl-lysine through non-organic solvent method | 河南中医学院 | 2017-05-17 | — | — | CN | claimed |
| CN-104968352-A | Use of acetylsalicylic acid to prevent and/or treat diabetic wounds | URGO LAB | 2015-10-07 | — | — | CN | claimed |
| CN-104586874-A | Medicine for preventing and treating respiratory tract infection of birds and preparation method thereof | LANZHOU INST ANIMAL SCIENCE & VETERINARY PHARMACEUTICS CAAS | 2015-05-06 | — | — | CN | claimed |
| CN-1118280-C | Bioactive concentrate, method for producing same and certain pharmaceutical compositions also containing chondroitin sulfate | S C TEHMAN SRL (RO) | 2003-08-20 | — | — | CN | claimed |
| CN-1181017-A | Bioactive concentrate, method for producing same and certain pharmaceutical compositions also containing chondroitin sulfate | S C TEHMAN SRL (RO) | 1998-05-06 | — | — | CN | claimed |
| EP-0297107-A4 | PRODUCTION OF STABLE CRYSTALLINE SODIUM ACETYLSALICYLATE. | PHARMACONTROL CORP (US) | 1989-06-14 | — | — | EP | claimed |
| EP-0297107-A1 | PRODUCTION OF STABLE CRYSTALLINE SODIUM ACETYLSALICYLATE | PHARMACONTROL CORP. (US) | 1989-01-04 | — | — | EP | claimed |
| WO-1988007859-A1 | STABLE SODIUM ASPIRIN TABLET COMPOSITIONS | PHARMACONTROL CORP. (US) | 1988-10-20 | — | — | WO | claimed |
| CN-86102837-A | Preparation of stable crystal of sodium acetylsalicylate | — | 1987-09-02 | — | — | CN | claimed |
| WO-1987005010-A1 | PRODUCTION OF STABLE CRYSTALLINE SODIUM ACETYLSALICYLATE | PHARMACONTROL CORP. (US) | 1987-08-27 | — | — | WO | claimed |
| US-4686212-A | Stable sodium aspirin tablet compositions | PHARMACONTROL CORP. (US) | 1987-08-11 | — | — | US | claimed |
| EP-0213761-A2 | Stable sodium aspirin tablet compositions | PHARMACONTROL CORP. (US) | 1987-03-11 | — | — | EP | claimed |
| US-3985792-A | Stable sodium acetylsalicylate and method for its manufacture | PHARMACONTROL CORP, A DE CORP. | 1976-10-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211621-A1 | LIPOSOMAL SUSTAINED-RELEASE COMPOSITIONS CONTAINING A THERAPEUTIC DRUG AND USE THEREOF | LIPA, LPXN, SGMS2 | PTGS1 2168/4885PTGS2 1770/4885KDM4E 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.